Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.verified

REGN

Price:

$843.6

Market Cap:

$91.46B

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carci...[Read more]

Industry

Biotechnology

IPO Date

1991-04-02

Stock Exchange

NASDAQ

Ticker

REGN

The Enterprise Value as of November 2024 (TTM) for Regeneron Pharmaceuticals, Inc. (REGN) is 92.15B

According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 92.15B. This represents a change of -13.79% compared to the average of 106.89B of the last 4 quarters.

Regeneron Pharmaceuticals, Inc. (REGN) Historical Enterprise Value (quarterly & annually)

How has REGN Enterprise Value performed in the past?

The mean historical Enterprise Value of Regeneron Pharmaceuticals, Inc. over the last ten years is 56.64B. The current 92.15B Enterprise Value has changed 16.17% with respect to the historical average. Over the past ten years (40 quarters), REGN's Enterprise Value was at its highest in in the June 2024 quarter at 115.04B. The Enterprise Value was at its lowest in in the September 2019 quarter at 31.01B.

Quarterly (TTM)
Annual

Average

56.64B

Median

49.41B

Minimum

40.10B

Maximum

93.69B

Regeneron Pharmaceuticals, Inc. (REGN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 51.52%

Maximum Annual Enterprise Value = 93.69B

Minimum Annual Increase = -31.39%

Minimum Annual Enterprise Value = 40.10B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202393.69B21.88%
202276.87B15.48%
202166.57B26.83%
202052.48B30.89%
201940.10B-4.80%
201842.12B-3.10%
201743.46B1.98%
201642.62B-31.39%
201562.12B34.06%
201446.34B51.52%

Regeneron Pharmaceuticals, Inc. (REGN) Average Enterprise Value

How has REGN Enterprise Value performed in the past?

The current Enterprise Value of Regeneron Pharmaceuticals, Inc. (REGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

79.04B

5-year avg

65.94B

10-year avg

56.64B

Regeneron Pharmaceuticals, Inc. (REGN) Enterprise Value vs. Peers

How is REGN’s Enterprise Value compared to its peers?

Regeneron Pharmaceuticals, Inc.’s Enterprise Value is greater than CRISPR Therapeutics AG (4.07B), less than Novo Nordisk A/S (3.42T), greater than Sarepta Therapeutics, Inc. (12.74B), greater than Intellia Therapeutics, Inc. (1.48B), greater than Incyte Corporation (13.39B), greater than Alnylam Pharmaceuticals, Inc. (35.37B), greater than United Therapeutics Corporation (15.54B), greater than Ultragenyx Pharmaceutical Inc. (5.14B), greater than Apellis Pharmaceuticals, Inc. (3.52B), greater than PTC Therapeutics, Inc. (2.85B), greater than Reata Pharmaceuticals, Inc. (6.68B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Krystal Biotech, Inc. (4.73B), greater than Madrigal Pharmaceuticals, Inc. (6.71B), greater than BeiGene, Ltd. (22.23B), greater than BioMarin Pharmaceutical Inc. (-68141492200.00), greater than ImmunoGen, Inc. (8.19B), greater than Prometheus Biosciences, Inc. (9.47B), greater than Arrowhead Pharmaceuticals, Inc. (2.81B), greater than Ionis Pharmaceuticals, Inc. (7.80B),

Build a custom stock screener for Regeneron Pharmaceuticals, Inc. (REGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Regeneron Pharmaceuticals, Inc. (REGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Regeneron Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 3-year average Enterprise Value for Regeneron Pharmaceuticals, Inc. (REGN)?

What is the 5-year average Enterprise Value for Regeneron Pharmaceuticals, Inc. (REGN)?

How does the current Enterprise Value for Regeneron Pharmaceuticals, Inc. (REGN) compare to its historical average?